TX-MAVENIR
17.3.2022 14:03:02 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announces its complete Software as a Service (SaaS) based Business Communications portfolio, including customer engagement, business messaging, Communications Platform as a Service (CPaaS), Unified Communications as a Service (UCaaS) and Contact Center as a Service (CCaaS).
Mavenir leverages its global expertise in mobile networks, its relationships with hundreds of CSPs, enterprises and partners, and its leadership in the mobile messaging space to provide a Business Communications portfolio that enables omni-channel customer experiences to businesses of all sizes. The MAVbiz portfolio includes the following solutions:
> |
Mavenir Engage — Customer Engagement as a Service solution that combines multi-channel business messaging connectors (SMS, RCS, Apple Messages for Business, Google Business Messages) with business automations, chatbots, visual flow builder and campaign manager capabilities to enable conversational commerce capabilities for businesses of all sizes. |
||||
> |
Mavenir CPaaS — A full set of programmable APIs and turnkey applications (Smart 2FA, Number Masking, Call Routing) that allow businesses and developers to integrate communication capabilities into business processes and applications. |
||||
> |
Mavenir Connect — Unified Communication as a Service (UCaaS) solution that delivers a powerful set of high-definition voice, video, messaging, and meetings capabilities to allow workers to collaborate with colleagues and connect with customers anywhere, anytime and on any device. |
||||
> |
Mavenir Care — Contact Center as a Service (CCaaS) solution with omni-channel integrations, flexible and open APIs, business processes integrations (CRMs, AI platforms), visual IVR builder, and robust analytics and reporting. |
“Gartner predicts that 80% of customer service organizations will abandon mobile apps in favor of messaging by 2025i ," said Jorgen Nilsson, President, Enterprise Connect Business, Mavenir. “As a leader in messaging, with 60% SMS market shareii and over 3 billion mobile messaging subscribers globally, Mavenir is unlocking the power of business messaging to create a superior customer experience, leveraging our messaging footprint, certification as an Apple Messages for Business MSP and other key ecosystem partnerships.”
Mavenir’s Business Communications Solutions are designed to fit the needs of businesses of all sizes, micro, small and medium businesses to large enterprises, and are brought to market through CSPs, Channels or SIs, which can apply their own brand to the solutions and leverage Mavenir’s professional services, white-label marketing collateral, business operations and partner ecosystem relationships for fast time-to-market and subscriber growth.
Mavenir’s solutions deliver omni-channel interactions in every aspect of business communications and enable businesses with an affordable and fast enablement of their digital presence. By combining these solutions businesses can:
> |
Use Mavenir Engage chatbots and automations to offload repetitive tasks but leverage the human-in-the-loop (HITL) API to transfer messaging conversations to a representative using a Mavenir Care agent console |
||||
> |
Use Mavenir CPaaS APIs to send calls or text conversations from a business website or application to an employee using a Mavenir Connect endpoint. |
||||
> |
Transfer a customer call from the Mavenir Care agent console to another employee using a Mavenir Connect endpoint. |
||||
> |
Deflect incoming calls from the Mavenir Care contact center to a Mavenir Engage chatbot during busy hours or when the business is closed. |
Market dynamics are pointing towards omni-channel messaging in all aspects of business communication. 79% of consumers prefer live chats because they offer instant responsesiii and 53% of businesses saw an increase in workload due to the pandemiciv . Messaging increases productivity by allowing employees to handle multiple communications simultaneously.
Mavenir will be showcasing its Business Communications portfolio at Enterprise Connect 2022. Booth #1500 from March 21 to 24 in Orlando, Florida.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
| ______________________________ |
i Source: Gartner Newsroom |
ii Source: Mavenir based on GSMA Operator Subscribers |
iii Source: 99 Firms – Live Chat Statistics |
iv Source: User Testing – 2021 CX Industry Report |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005116/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom